ANN ARBOR, MI, United States, via eTeligis Inc., 05/27/2014 - - Tangent Medical (www.tangentmedical.com), an innovator of IV therapy products, announced it has received CE Mark approval for the NovaCath™ Integrated IV Catheter System. The approval demonstrates that NovaCath meets the safety, health and environmental requirements in the European Union and clears the company to introduce NovaCath throughout Europe and other countries recognizing the CE Mark.
"This is another significant milestone for Tangent Medical and an important achievement as it allows us to begin selling NovaCath (http://www.tangentmedical.com/video) in Europe," said Tangent Medical President Eric Sandberg. "NovaCath is a breakthrough technology designed to address IV therapy challenges common throughout the world. Receiving CE Mark approval gives us the opportunity to advance the safety and efficacy of IV therapy for patients, clinicians, and hospitals in additional international markets."
"NovaCath uniquely integrates several patented design elements that not only reduce the risk of IV complications but also improve healthcare worker safety and clinical efficiency," said Curtis Bloch, Vice President of Sales & Marketing for Tangent Medical. "Our innovative, award- winning design delivers advanced catheter stabilization, next-generation tubing management, passive needle encapsulation and blood control on every short-peripheral IV start. Feedback from clinicians has been exceptional. We look forward to introducing NovaCath in Europe."
About NovaCath
The NovaCath™ Integrated IV Catheter System integrates a series of next-generation technologies designed to address IV therapy challenges including catheter stabilization, healthcare worker safety, tubing management and patient comfort. NovaCath is the only peripheral IV catheter with advanced catheter stabilization designed to exceed the highest CDC, OSHA and INS standards for IV catheter stabilization. Its passive needle shielding technology and closed system design minimize risk of needlestick injuries and occupational exposure to blood to the lowest feasible extent. Several novel design features uniquely position NovaCath to offer healthcare facilities uncompromising safety and satisfaction -- both to the clinician and the patient.
About Tangent Medical
Tangent Medical is focused on the development and commercialization of IV therapy products. Founded in 2009, the company's patented NovaCath™ Integrated IV Catheter System is the only safety IV catheter to cost-effectively combine advanced catheter stabilization, passive needle encapsulation, tubing management and blood control. Based on extensive clinical research into the needs of both healthcare workers and patients, this next-generation system is designed to establish a new standard in catheter design, functionality and performance. For more information, visit www.tangentmedical.com.
Contact Information
John Sperrazzo
Eye-To-Eye Communications, Inc.
john@eyetoeyepr.com
858-361-4495
SOURCE: Tangent Medical Technologies, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
Tangent_Medical_05-27-2014_MEL_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment